Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
“We need all the capital we can get our hands on," the company states.
Lilly, Merck & Co and Verastem could take on Amgen, Bristol and Revolution.
Amid a KRAS data dump, a doublet of RMC-6236 and RMC-6291 was a highlight.
Conferences ramp up, and ASH abstracts near.
RMC-9805 looks more efficacious, and less toxic, than Astellas’s G12D degrader in pancreatic cancer.
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.